Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies SUNRISE-FA 2 pivotal study for LX2006 on track to initiate in...
SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design BLA supportive manufacturing...
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today...
SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026; Awaiting final FDA feedback Multiple presentations highlighting progress across cardiac genetic medicine...
Barchart Research What to Expect from LXEO Earnings LXEO Generated May 8, 2026 Current Price $5.83 EPS Estimate $$-0.29 Consensus Rating Strong Buy Average Move 8.80% Lexeo Therapeutics Reports Monday...
Barchart Research What to Expect from LXEO Earnings LXEO Generated May 8, 2026 Current Price $5.83 EPS Estimate $$-0.29 Consensus Rating Strong Buy Average Move 8.80% Lexeo Therapeutics Reports Monday...
Barchart Research What to Expect from LXEO Earnings LXEO Generated May 8, 2026 Current Price $5.83 EPS Estimate $$-0.29 Consensus Rating Strong Buy Average Move 8.80% Lexeo Therapeutics Reports Monday...
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced...
SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026 First CMC Development and Readiness...
Barchart Research What to Expect from LXEO Earnings LXEO Generated March 28, 2026 Current Price $5.46 EPS Estimate $-0.32 Consensus Rating Strong Buy Average Move 8.90% LXEO's Cardiac Gene Therapy Data...